Children's Hospital Medical Center, Cincinnati

571 total trials 106 currently recruiting 372 completed

Children's Hospital Medical Center, Cincinnati sponsors 571 registered US clinical trials on ClinicalTrials.gov, 106 of them currently recruiting, and 372 completed. 38 of these trials are in Phase 3-4 (later-stage) and 140 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Autism Spectrum Disorder, with 13 trials.

Trial Pipeline

571 total, page 12 of 12

COMPLETED

Follow-up of Adolescent Bariatric Surgery

NCT00776776

COMPLETED Phase 2

Trial of Growth Hormone Therapy in Pediatric Crohn's Disease

NCT00109473

COMPLETED NA

Role of Carbohydrate Modification in Weight Management Among Obese Children

NCT00215111

TERMINATED Phase 4

Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease

NCT00115336

COMPLETED Phase 3

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

NCT00221403

COMPLETED Phase 3

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study

NCT00088452

COMPLETED Phase 1

Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia

NCT00243399

COMPLETED Phase 3

Coping Skills Training for Adolescents With Fibromyalgia

NCT00086047

COMPLETED NA

Randomized Controlled Trial of Multi-Source Feedback to Pediatric Residents

NCT00302783

COMPLETED

Facilitated Referral for Children Screening Positive for Mental Illness

NCT00448331

COMPLETED Phase 2

Triptorelin for Ovary Protection in Childhood Onset Lupus

NCT00124514

COMPLETED Phase 1

Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)

NCT00166595

COMPLETED Phase 2

Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM

NCT00457808

TERMINATED Phase 2

Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis

NCT00035958

COMPLETED Phase 1

Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)

NCT00147394

COMPLETED Phase 1

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

NCT00266565

COMPLETED Phase 3

Lithium Versus Divalproex for Treating Pediatric Bipolar Disorder

NCT00221429

COMPLETED Phase 2

Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease

NCT00004488

COMPLETED NA

Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants

NCT00004410

COMPLETED NA

Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis

NCT00004441

COMPLETED Phase 2

Calcium Supplements for Bone Health in Juvenile Rheumatoid Arthritis

NCT00000429

← Previous Page 12 of 12

Phase Distribution

PhaseTrial count
Phase 1 86
Phase 2 54
Phase 3 15
Phase 4 23

What the Pipeline for Children's Hospital Medical Center, Cincinnati Shows

According to the ClinicalTrials.gov registry, Children's Hospital Medical Center, Cincinnati is linked to 571 US clinical trials across every stage of research activity. Of those, 106 studies are currently recruiting, about 19% of the sponsor's indexed portfolio, and 372 are already marked complete, representing roughly 65% of the total.

The phase mix for Children's Hospital Medical Center, Cincinnati reports 38 late-stage studies (Phase 3 and Phase 4 combined) and 140 earlier-phase studies (Phase 1 and Phase 2).

The top therapeutic focus area indexed for Children's Hospital Medical Center, Cincinnati is Autism Spectrum Disorder with 13 linked trials, and 9 other condition areas appear in the top list above.

How to read these pipeline numbers

Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.